DrugPatentWatch Database Preview
VIEKIRA PAK (COPACKAGED) Drug Profile
Email this page to a colleague
When do Viekira Pak (copackaged) patents expire, and when can generic versions of Viekira Pak (copackaged) launch?
Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are seventeen patents protecting this drug.
This drug has six hundred and thirteen patent family members in fifty-three countries.
The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.
DrugPatentWatch® Generic Entry Outlook for Viekira Pak (copackaged)
Viekira Pak (copackaged) was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 18, 2033. This may change due to patent challenges or generic licensing.
There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VIEKIRA PAK (COPACKAGED)
| International Patents: | 613 |
| US Patents: | 17 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA PAK (COPACKAGED) |
| DailyMed Link: | VIEKIRA PAK (COPACKAGED) at DailyMed |
-patent-expirations.png "VIEKIRA PAK (COPACKAGED) drug patent expirations")
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIEKIRA PAK (COPACKAGED)
Generic Entry Date for VIEKIRA PAK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
ATC Classes for VIEKIRA PAK (COPACKAGED)
US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)
Expired US Patents for VIEKIRA PAK (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | Get Started Free | Get Started Free |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | Get Started Free | Get Started Free |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | Get Started Free | Get Started Free |
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | Get Started Free | Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIEKIRA PAK (COPACKAGED)
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 103054 | Get Started Free |
| World Intellectual Property Organization (WIPO) | 2013059630 | Get Started Free |
| Hungary | E026832 | Get Started Free |
| Japan | 5911838 | Get Started Free |
| Canada | 2847910 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340029 | 599 | Finland | Get Started Free | |
| 2692346 | PA2017033,C2692346 | Lithuania | Get Started Free | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2340029 | 1590012-9 | Sweden | Get Started Free | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119 |
| 2692346 | 300901 | Netherlands | Get Started Free | PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| 2340029 | 15C0021 | France | Get Started Free | PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
